Haoxi Health Technology Limited Class A (HAO) AI Stock Analysis

• Market Cap: $12.86M
• Dividend Yield: N/A
• Average Volume (3M): 970.53K
• Price to Earnings (P/E): 1.2
• Beta (1Y): 1.57
• Revenue Growth: -32.39%
• EPS Growth: 41.48%
• Country: US
• Employees: 30
• Sector: Communication Services
• Sector Strength: 97
• Industry: Advertising Agencies
• EPS (TTM): 0.01
• Shares Outstanding: 7,503,028
• 10 Day Avg. Volume: 34,415
• 30 Day Avg. Volume: 970,526
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: $1.50 ▲(29.31% Upside)

The overall score reflects a combination of strong valuation, with the stock appearing undervalued, and moderate financial performance, highlighted by revenue growth but hampered by cash flow issues. Technical analysis indicates a lack of strong momentum, contributing to the overall risk profile.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product adoption, suggesting a robust demand for the company's offerings.

Improved Profitability

Improved profitability reflects effective cost control and operational efficiency, enhancing the company's financial health and competitive position.

Strong Balance Sheet

A strong balance sheet with low leverage provides financial stability and flexibility, supporting long-term growth and investment opportunities.

Negative Factors

Cash Flow Challenges

Negative operating cash flow indicates difficulties in generating cash from operations, which may hinder the company's ability to fund growth and meet obligations.

Reliance on Liabilities

Reliance on liabilities can increase financial risk, potentially impacting the company's ability to weather economic downturns or financial stress.

Operational Efficiency

Suboptimal operational efficiency suggests potential for cost reductions and process improvements, which are crucial for enhancing profitability and competitiveness.

Haoxi Health Technology Limited Class A Business Overview & Revenue Model

Company Description

Haoxi Health Technology Limited, through its subsidiaries, provides online marketing solutions in China. It offers online marketing solutions, including online short video marketing solutions to advertisers through its media partners; and customized marketing solutions by planning, producing, placing, and optimizing online ads to help advertisers acquire, convert, and retain consumers on various online media platforms. The company places its ads through mainstream online short video and social media platforms, such as Toutiao, Douyin, WeChat, and Sina Weibo. It serves advertiser client base primarily in the healthcare industry. The company was founded in 2018 and is based in Beijing, China.

How the Company Makes Money

Haoxi Health Technology generates revenue through multiple streams, including the sale of medical devices and health monitoring systems directly to healthcare providers and institutions. Additionally, the company offers subscription-based services for its telemedicine platforms, which allow patients to consult with healthcare professionals remotely. Partnerships with hospitals and clinics play a significant role in driving sales and expanding market reach. Furthermore, HAO may benefit from government contracts and grants aimed at advancing health technology solutions, contributing to its overall earnings.

Haoxi Health Technology Limited Class A Financial Statement Overview

Summary

Haoxi Health Technology Limited Class A shows promising growth in revenue and profitability, with improved margins and a stronger balance sheet. However, cash flow challenges persist, highlighting the need for improved cash management. The company is on a positive trajectory but must address cash flow issues to ensure long-term sustainability.

Income Statement

The company has shown strong revenue growth, with a significant increase from $28.2M in 2023 to $48.5M in 2024. Gross profit margin improved slightly, indicating better cost management. Net profit margin also improved, reflecting enhanced profitability. However, the EBIT and EBITDA margins indicate room for further operational efficiency improvements.

Balance Sheet

The company's debt-to-equity ratio is low, suggesting conservative leverage. The return on equity is positive, reflecting profitability, but the equity ratio indicates a reliance on liabilities. The significant increase in stockholders' equity is a positive sign, but past negative equity raises concerns about historical financial stability.

Cash Flow

Operating cash flow remains negative, which is a concern for sustainability. However, the company has improved its free cash flow position compared to previous years. The free cash flow to net income ratio indicates challenges in converting profits into cash, suggesting a need for better cash management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	32.80M	32.80M	48.52M	28.23M	16.16M	12.85M
Gross Profit	927.75K	927.75K	2.75M	2.06M	648.72K	605.58K
EBITDA	4.21M	4.57M	1.79M	1.22M	271.77K	330.96K
Net Income	3.88M	3.88M	1.29M	969.75K	244.59K	304.06K
Balance Sheet
Total Assets	21.60M	21.60M	15.51M	4.46M	542.99K	2.81M
Cash, Cash Equivalents and Short-Term Investments	8.62M	8.62M	6.66M	1.20M	293.51K	55.89K
Total Debt	1.99M	1.99M	1.20M	850.06K	505.40K	335.03K
Total Liabilities	4.22M	4.22M	4.23M	2.90M	2.01M	4.74M
Stockholders Equity	17.38M	17.38M	11.27M	1.57M	-1.47M	-1.93M
Cash Flow
Free Cash Flow	-3.36M	-3.36M	-802.94K	-917.63K	-684.06K	2.65M
Operating Cash Flow	-3.36M	-3.36M	-747.58K	-872.13K	-675.36K	2.65M
Investing Cash Flow	-3.58M	-3.58M	-3.13M	-45.50K	-8.70K	-3.26K
Financing Cash Flow	8.90M	8.90M	9.32M	1.80M	933.22K	-2.61M

Haoxi Health Technology Limited Class A Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.16
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAO, the sentiment is Positive. The current price of 1.16 is above the 20-day moving average (MA) of 1.11, above the 50-day MA of 1.03, and below the 200-day MA of 1.22, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 84.96 is Negative, neither overbought nor oversold. The STOCH value of 92.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HAO.

Haoxi Health Technology Limited Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CHR	70 Outperform	$9.34M	0.02	7.01%	―	-5.65%	-41.43%
HAO	68 Neutral	$12.86M	1.20	2.92%	―	-32.39%	41.48%
Sector *	60 Neutral	$48.67B	4.58	-11.27%	4.14%	2.83%	-41.78%
CNET	44 Neutral	$4.09M	-1.42	-50.26%	―	-66.59%	67.63%
DRCT	39 Underperform	$24.26M	-0.03	―	―	-62.46%	-12.90%

Haoxi Health Technology Limited Class A Corporate Events

Haoxi Health Technology Approves Major Shareholder Changes at December Meeting

On December 8, 2025, Haoxi Health Technology Limited held an extraordinary general meeting where shareholders approved several significant changes. These included increasing the voting rights of Class B shares from ten to thirty votes, expanding the authorized share capital, and consolidating shares at a ratio determined by the board. These changes aim to enhance the company’s governance structure and financial flexibility, potentially impacting its market positioning and shareholder value.

The most recent analyst rating on (HAO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Haoxi Health Technology Limited Class A stock, see the HAO Stock Forecast page.

Haoxi Health Technology Secures $5 Million in Private Placement

On November 26, 2025, Haoxi Health Technology Limited entered into a Securities Purchase Agreement with several non-U.S. investors for a private placement of 6,250,000 Class A ordinary shares and 12,500,000 warrants, raising gross proceeds of $5 million. The closing of this offering occurred on December 3, 2025, with the funds intended for working capital and general corporate purposes. This strategic move is expected to strengthen the company’s financial position and support its operational growth, potentially enhancing its market presence and providing benefits to its stakeholders.

The most recent analyst rating on (HAO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Haoxi Health Technology Limited Class A stock, see the HAO Stock Forecast page.

Haoxi Health Technology Announces Extraordinary General Meeting for Governance and Capital Changes

Haoxi Health Technology Limited announced an extraordinary general meeting of shareholders scheduled to discuss significant proposals, including increasing the voting rights of Class B shares and expanding the authorized share capital. These changes, if approved, could enhance the company’s governance structure and financial flexibility, impacting shareholder value and market positioning.

The most recent analyst rating on (HAO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Haoxi Health Technology Limited Class A stock, see the HAO Stock Forecast page.

Haoxi Health Technology Closes $1.2 Million Private Placement

Haoxi Health Technology Limited, a company engaged in the health technology sector, announced the successful closing of a private placement on October 22, 2025. The company sold 5,217,391 Class A ordinary shares at $0.23 per share, raising $1.2 million in gross proceeds. These funds are intended for working capital and general corporate purposes, potentially strengthening the company’s financial position and operational capabilities.

The most recent analyst rating on (HAO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Haoxi Health Technology Limited Class A stock, see the HAO Stock Forecast page.

Haoxi Health Technology Secures $1.2 Million Through Private Placement

On October 13, 2025, Haoxi Health Technology Limited entered into a securities purchase agreement with non-U.S. investors to sell 5,217,391 Class A ordinary shares for approximately $1.2 million. The proceeds from this private placement will be used for working capital and general corporate purposes, potentially strengthening the company’s financial position and operational capabilities.

The most recent analyst rating on (HAO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Haoxi Health Technology Limited Class A stock, see the HAO Stock Forecast page.